雷珠单抗在新生血管性青光眼复合式小梁切除术围手术期的应用

Application of Ranibizumab at perioperative period of compound trabeculectomy in patients with neovascular glaucoma

目的:观察新生血管性青光眼复合式小梁切除术围手术期进行玻璃体内注射雷珠单抗(ranibizumab)对虹膜新生血管及眼压的影响。方法:对2013-01/2014-01收治于安阳市眼科医院药物不能控制的38例38眼新生血管性青光眼患者,行ranibizumab玻璃体内注射+复合式小梁切除术+全视网膜光凝术。术后随访6mo,观察治疗前后虹膜新生血管、眼压及视力变化。结果:玻璃体内注药后7d,36例(94.74%)虹膜新生血管完全消退,2例(5.26%)虹膜细小血管全部消退,残留少许粗大血管。复合式小梁切除术后1mo,所有病例虹膜新生血管均消退;术后3mo,8例(21.05%)虹膜新生血管再次出现,行ranibizumab玻璃体内注射;术后6mo,所有患者均未见虹膜新生血管。注药前平均眼压为42.82±10.29mmHg,注药后5d为39.13±9.71mmHg,注药前后眼压变化无统计学意义(q=2.65,P>0.05)。复合式小梁切除术后1wk,1、3、6mo,眼压分别为10.53±1.81、10.11±1.73、11.29±2.49、12.58±3.01mmHg,与注药前相比有统计学差异(q=23.15、23.46、22.61、21.68,均P<0.01)。复合式小梁切除术后1wk,1、3、6mo患者眼压与注药后5d相比有统计学意义(q=20.51、20.81、19.96、19.04,均P<0.01)。复合式小梁切除术成功率为73.68%。随访6mo,24例(63.16%)视力较术前提高,14例(36.84%)视力保持不变。结论:新生血管性青光眼围手术期应用ranibizumab玻璃体内注射,可有效提高复合式小梁切除术成功率,减少手术并发症,疗效安全肯定。

AIM：To observe the effect of intravitreal injection of Ranibizumab at perioperative period of compound trabeculectomy on iris neovascularization, intraocular pressure（IOP）for patients with neovascular glaucoma（NVG）. METHODS：Intravitreal injection of ranibizumab, compound trabeculectomy and panretinal photocoagulation were given to 38 patients（38 eyes）with neovascular glaucoma, which could not be controlled by drugs, from January 2013 to January 2014 in Anyang Eye Hospital. Iris neovascularization, IOP and changes of visual acuity were observed before and after treatments. The patients were followed up for 6mo after treatments. RESULTS： Seven days after intravitreal injection, 36 cases（94.74%）had complete regression of iris neovascularization. Two cases（5.26%）had regression of small blood vessels in the iris, a little thick blood vessels were remained. At 1mo after compound trabeculectomy, iris neovascularization in all patients were subsided; at 3mo after treatments, the iris neovascularization in 8 patients（21.05%）were performed again, and accepted intravitreal injection of ranibizumab again. Six months after the first treatments, all patients showed no iris neovascularization. The mean IOP before injection was 42.82±10.29mmHg. At 5d after the drug injection was 39.13±9.71mmHg. Before and after the drug injection, change of IOP was not statistically significant（q=2.65, P〉0.05）. At 1wk,1,3 and 6mo after compound trabeculectomy, IOP was 10.53±1.81mmHg, 10.11±1.73mmHg, 11.29±2.49mmHg, 12.58±3.01mmHg,which decreased significantly（q=23.15,23.46,22.61,21.68, all P〈0.01）compared with that before injection. Compared with the IOP at 5d after compound trabeculectomy, the IOP at 1wk,1,3 and 6mo decreased significantly（q=20.51,20.81,19.96,19.04, all P〈0.01）. The success rate of compound trabeculectomy was 73.68%. Followed up for 6 mo, visual acuity in 24 cases（63.16%）improved and in 14 cases（36.84%）remained unchanged. CONCLUSION： Intravitreal injection of ranibizumab at perioperative period of compound trabeculectomy can effectively improve the success rate of the surgeries and reduce risk of complications, and the effect is certainly safe.